HDFC LIFE INSURANCE COMPANY LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 596.6 INR | +0.57% |
|
+2.70% | -7.74% |
| 06-20 | INDIA STOCKS-Indian shares muted as financials, pharma stocks weigh | RE |
| 06-13 | Indian Equities End Higher, Buoyed by Positive Global Cues Due to US Inflation Data | MT |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
Strengths
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The opinion of analysts covering the stock has improved over the past four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- Low profitability weakens the company.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 67.8 times its estimated earnings per share for the ongoing year.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is not the most generous with respect to shareholders' compensation.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Life & Health Insurance
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -7.74% | 15.29B | B | ||
| +10.47% | 99.44B | B- | ||
| +2.78% | 95.03B | B | ||
| -22.12% | 75.73B | B+ | ||
| +20.29% | 75.17B | D+ | ||
| +26.92% | 31.26B | B | ||
| +20.99% | 31.32B | A | ||
| +3.34% | 17.56B | C+ | ||
| +21.17% | 12.7B | A- | ||
| +12.89% | 10.36B | B+ |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
-
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- HDFCLIFE Stock
- Ratings HDFC Life Insurance Company Limited
